These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

604 related items for PubMed ID: 29377257

  • 1. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

  • 2. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S, Boy M, Chow V, Chan G.
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [Abstract] [Full Text] [Related]

  • 3. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
    Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A.
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294
    [Abstract] [Full Text] [Related]

  • 4. Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
    Krishnaswami S, Wang T, Yuan Y, Alvey CW, Checchio T, Peterson M, Shi H, Riese R.
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):395-9. PubMed ID: 27137149
    [Abstract] [Full Text] [Related]

  • 5. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
    Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G.
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
    Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, Goodhand JR, Ahmad T, Satsangi J, Irving PM, Kennedy NA, LEO [London, Exeter, Oxford] IBD Research Consortium .
    J Crohns Colitis; 2020 Oct 05; 14(10):1385-1393. PubMed ID: 32280965
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W, Study A3921063 Investigators.
    N Engl J Med; 2012 Aug 16; 367(7):616-24. PubMed ID: 22894574
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E.
    Gut; 2017 Jun 16; 66(6):1049-1059. PubMed ID: 28209624
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C.
    Aliment Pharmacol Ther; 2020 Jan 16; 51(2):271-280. PubMed ID: 31660640
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.